Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
RLYB Quote, Financials, Valuation and Earnings
Last price:
$8.37
Seasonality move
:
-3.66%
Day range:
$8.20 - $8.45
52-week range:
$1.76 - $11.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
150.02x
P/B ratio:
0.77x
Volume:
14.6K
Avg. volume:
247K
1-year change:
81.68%
Market cap:
$44.4M
Revenue:
$858K
EPS (TTM):
-$0.21
Analysts' Opinion
-
Consensus RatingRallybio Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $1.00, Rallybio Corp. has an estimated downside of -5.1% from its current price of $8.43.
-
Price Target UpsideAccording to analysts, the highest upside price target is $1.00 representing -100% upside increase from its current price of $8.43.
Fair Value
-
According to the consensus of 2 analysts, Rallybio Corp. has -5.1% downside to fair value with a price target of $1.00 per share.
RLYB vs. S&P 500
-
Over the past 5 trading days, Rallybio Corp. has underperformed the S&P 500 by -3.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Rallybio Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rallybio Corp. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Rallybio Corp. reported revenues of $222K.
Earnings Growth
-
Rallybio Corp. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Rallybio Corp. reported earnings per share of -$1.11.
Enterprise value:
-10M
EV / Invested capital:
--
Price / LTM sales:
150.02x
EV / EBIT:
--
EV / Revenue:
-11.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$766K
Return On Assets:
-14.62%
Net Income Margin (TTM):
-1046.39%
Return On Equity:
-15.88%
Return On Invested Capital:
-15.84%
Operating Margin:
-2888.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $636K | $858K | $38K | $222K | |
| Gross Profit | -$150K | $505K | $766K | $8K | $219K | |
| Operating Income | -$78.9M | -$60.5M | -$29.7M | -$11.6M | -$6.4M | |
| EBITDA | -$78.8M | -$60.4M | -$29.6M | -$11.6M | -$6.4M | |
| Diluted EPS | -$1.84 | -$3.07 | -$0.21 | -$1.98 | -$1.11 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $180.9M | $179.5M | $114.8M | $67.8M | $61.3M | |
| Total Assets | $182.2M | $180.4M | $115.6M | $68.1M | $62.3M | |
| Current Liabilities | $6.6M | $10.7M | $9.3M | $6.2M | $4.2M | |
| Total Liabilities | $6.6M | $11.1M | $9.4M | $6.5M | $4.3M | |
| Total Equity | $175.6M | $169.3M | $106.2M | $61.7M | $58M | |
| Total Debt | -- | $374K | $173K | -- | $82K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.3M | -$49.3M | -$29.8M | -$9.9M | -$4.7M | |
| Cash From Investing | $27.7M | $33.5M | $47.3M | -$1.6M | $3.9M | |
| Cash From Financing | $143K | $5.2M | $16K | $18K | $6K | |
| Free Cash Flow | -$60.3M | -$49.3M | -$29.8M | -$9.9M | -$4.7M | |
RLYB
Sector
Market Cap
$44.4M
$23.9M
Price % of 52-Week High
73.37%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.02%
-1.9%
1-Year Price Total Return
81.68%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.47
200-day SMA
Buy
Level
$5.28
Bollinger Bands (100)
Buy
Level
4.52 - 8.22
Chaikin Money Flow
Sell
Level
-259.1K
20-day SMA
Sell
Level
$9.20
Relative Strength Index (RSI14)
Sell
Level
49.91
ADX Line
Buy
Level
21.64
Williams %R
Neutral
Level
-74.0831
50-day SMA
Buy
Level
$7.24
MACD (12, 26)
Buy
Level
0.20
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
30.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.1257)
Sell
CA Score
(Annual)
Level (-0.4849)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.4444)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
Stock Forecast FAQ
In the current month, RLYB has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RLYB average analyst price target in the past 3 months is $1.00.
-
Where Will Rallybio Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rallybio Corp. share price will drop to $1.00 per share over the next 12 months.
-
What Do Analysts Say About Rallybio Corp.?
Analysts are divided on their view about Rallybio Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rallybio Corp. is a Sell and believe this share price will rise from its current level to $1.00.
-
What Is Rallybio Corp.'s Price Target?
The price target for Rallybio Corp. over the next 1-year time period is forecast to be $1.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RLYB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rallybio Corp. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RLYB?
You can purchase shares of Rallybio Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rallybio Corp. shares.
-
What Is The Rallybio Corp. Share Price Today?
Rallybio Corp. was last trading at $8.37 per share. This represents the most recent stock quote for Rallybio Corp.. Yesterday, Rallybio Corp. closed at $8.43 per share.
-
How To Buy Rallybio Corp. Stock Online?
In order to purchase Rallybio Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RLYB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RLYB
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
0.77x
1.72x
Price / LTM sales
150.02x
1.44x
Growth Metrics
RLYB
Sector
Revenue growth
484.21%
3.44%
Earnings growth
44.01%
14.97%
Revenue (5-year growth)
--
6.27%
Earnings forecast
-$1.20
-$0.22
Profitability
RLYB
Sector
Profitability FY 2025
$766K
$2.4M
Return on invested capital
-15.84%
-33.43%
Return on assets
-14.62%
-29.45%
Return on equity
-15.88%
-40.29%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Apr
4
Estimated Next Earnings Date
Jul
4
Balance Sheet
RLYB
Sector
Total cash
$54.7M
$25.6M
Short term investments
$51.6M
$22.7M
Total assets
$62.3M
$70.4M
Long term debt
$82K
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
